Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company. It undertakes the development and commercialization of novel, proprietary products and technologies, intended to make the blood supply safer. The company focuses on the development and commercialization of its flagship INTERCEPT Blood System based on its proprietary Helinx technology. Cerus has the worldwide rights of INTERCEPT for three blood components: platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It is marketed in Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cerus Corporation, Medical Equipment, Deals By Year, 2008 to YTD 2014 5
Cerus Corporation, Medical Equipment Deals By Type, 2008 to YTD 2014 6
Cerus Corporation, Medical Equipment, Deals By Region, 2008 to YTD 2014 7
Cerus Corporation, Medical Equipment, Deals By Market, 2008 to YTD 2014 8
Cerus Corporation, Medical Equipment, Deals Summary, 2008 to YTD 2014 9
Cerus Corporation, Medical Equipment, Deal Details 10
Partnerships 10
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 10
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 11
Cerus Enters Into Distribution Agreement With Ilex Biotech 12
Cerus Enters Into Agreement With CSL 13
Cerus Enters Into An Agreement With Grifols 14
Cerus Enters Into Co-Development Agreement With German Red Cross 15
Equity Offering 16
Cerus Completes Public Offering Of Shares For US$40.3 Million 16
Cerus Completes Underwritten Public Offering Of US$21 Million 18
Cerus Completes Private Placement Of Units For US$13.2 Million 20
Cerus Corporation - Key Competitors 22
Key Employees 23
Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Recent Developments 25
Financial Announcements 25
May 01, 2014: Cerus Reports First Quarter 2014 Results 25
Feb 25, 2014: Cerus Reports Fourth Quarter and Year-End 2013 Results 26
Oct 29, 2013: Cerus Corporation Reports Third Quarter 2013 Results 27
Oct 18, 2013: Cerus to Release Third Quarter 2013 Results on October 29, 2013 28
Jul 30, 2013: Cerus Corporation Reports Second Quarter 2013 Results 29
Jul 09, 2013: Cerus to Release Second Quarter 2013 Results on July 30, 2013 30
Apr 30, 2013: Cerus Reports Revenue Of $9.7m In Q1 2013 30
Feb 28, 2013: Cerus Reports Revenue Of $36.7m In 2012 31
Corporate Communications 32
Mar 25, 2014: Frank Witney Joins Cerus Board of Directors 32
Dec 11, 2013: Cerus Appoints North American Sales Team Leadership 33
Oct 21, 2013: Cerus Announces Appointment of Daniel Swisher as New Chair of Board of Directors 33
Government and Public Interest 34
Sep 04, 2013: Cerus to Present at the Baird's 2013 Health Care Conference on September 10, 2013 34
Aug 07, 2013: Cerus to Present at the Wedbush 2013 Life Sciences Management Access Conference on August 14, 2013 34
Product News 34
Dec 04, 2013: Cerus Submits Final Module in the Premarket Approval Application Process for INTERCEPT Plasma 34
Nov 06, 2013: Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Plasma 35
Nov 06, 2013: Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets 35
Oct 31, 2013: Cerus and the Swiss Red Cross Renew Commercial Contract with a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets 35
Oct 01, 2013: Cerus submits First Of Three Modules For Intercept Platelet Premarket Approval Application 36
Jun 11, 2013: Cerus Initiates Patient Enrollment In European Phase III Clinical Trials For Intercept Red Blood Cells For Acute And Chronic Anemia 36
May 28, 2013: Cerus Signs Intercept Platelet Agreement With Aalborg University Hospital In Denmark 37
Apr 24, 2013: Cerus Announces FDA Agreement On Modular PMA Submission Process For Intercept Platelets 37
Clinical Trials 38
Jun 11, 2013: Cerus Initiates Patient Enrollment In European Phase III Clinical Trials For Intercept Red Blood Cells For Acute And Chronic Anemia 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables

Cerus Corporation, Medical Equipment, Key Facts, 2013 1
Cerus Corporation, Medical Equipment, Deals By Year, 2008 to YTD 2014 1
Cerus Corporation, Medical Equipment, Deals By Region, 2008 to YTD 2014 1
Cerus Corporation, Medical Equipment, Deals By Market, 2008 to YTD 2014 1
Cerus Corporation, Medical Equipment, Deals Summary, 2008 to YTD 2014 1
Cerus Corporation, Medical Equipment, Deals By Year, 2008 to YTD 2014 5
Cerus Corporation, Medical Equipment Deals By Type, 2008 to YTD 2014 6
Cerus Corporation, Medical Equipment, Deals By Region, 2008 to YTD 2014 7
Cerus Corporation, Deals By Market, 2008 to YTD 2014 8
Cerus Corporation, Medical Equipment, Deals Summary, 2008 to YTD 2014 9
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 10
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 11
Cerus Enters Into Distribution Agreement With Ilex Biotech 12
Cerus Enters Into Agreement With CSL 13
Cerus Enters Into An Agreement With Grifols 14
Cerus Enters Into Co-Development Agreement With German Red Cross 15
Cerus Completes Public Offering Of Shares For US$40.3 Million 16
Cerus Completes Underwritten Public Offering Of US$21 Million 18
Cerus Completes Private Placement Of Units For US$13.2 Million 20
Cerus Corporation, Key Competitors 22
Cerus Corporation, Key Employees 23
Cerus Corporation, Subsidiaries 24

List of Figures

Cerus Corporation, Medical Equipment, Deals by Type, 2008 to YTD 2014 1
Cerus Corporation, Medical Equipment, Deals By Year, 2008 to YTD 2014 5
Cerus Corporation, Medical Equipment, Deals by Type, 2008 to YTD 2014 6
Cerus Corporation, Medical Equipment, Deals By Region, 2008 to YTD 2014 7
Cerus Corporation, Medical Equipment, Deals by Market, 2008 to YTD 2014 8

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

ApaTech Limited SWOT Analysis, Strategy, Revenues and Profits

ApaTech Limited SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Adtec Plasma Technology Co Ltd

Adtec Plasma Technology Co Ltd

  • $ 55
  • Company report
  • August 2014
  • by Wright Investors' Service

A textual analysis of the financial results for Adtec Plasma Technology Co Ltd compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ...

Glycorex Transplantation AB

Glycorex Transplantation AB

  • $ 55
  • Company report
  • September 2014
  • by Wright Investors' Service

A textual analysis of the financial results for Glycorex Transplantation AB compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio ...

Cord Blood America, Inc.

October 2014 $ 55

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.